OptiNose said today that it closed a $37 million Series D round led by Fidelity Management and Research Company. Avista Capital Partners, Entrepreneurs Fund and other current investors also contributed to the round.
The Yardley, Penn.-based company said it plans to use the newly-acquired funds to support commercial development of its lead product candidate, OPN-375, in the U.S.
OptiNose’s 1st commercial product is based on its Breath Powered platform, which the company said it uses to develop new systems capable of deep intranasal deposition of medication.
Get the full story at our sister site, Drug Delivery Business News.
